# Evolus Inc. (EOLS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $9.30, market value $614 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Evolus Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Free-cash-flow yield: -3.0%** (5-yr avg -10.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 66.7%**. Evolus Inc. keeps 66.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -5.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -17.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: 223.5%**. A 223.5% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -21.3%**. Return on all capital, debt included, is -21.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -15.2%**. Each dollar of assets produces -15.2% of profit.

## Growth
- **Revenue growth (1 yr): 11.6%** (3-yr 26.0%/yr, 5-yr 39.4%/yr). Revenue grew 11.6% over the last year, against 39.4% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1.2%**. Earnings per share rose 1.2%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. Evolus Inc. holds more cash than debt.
- **Altman Z-score: 2.18**. A Z-score of 2.18 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Evolus Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover Evolus Inc.; the consensus is strong_buy, with an average price target of $15.00 (+61% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 23.8%** (YTD 39.8%, 3-mo 39.4%). The shares are up 23.8% over twelve months including dividends.
- **From 52-week high: -0.1%** (140.9% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 73**. An RSI of 73 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.97** (volatility 67%). Beta of 0.97 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EOLS · Page: https://foliofundamentals.com/stocks/eols

Not investment advice.